Antifungal Agents for the Treatment of Systemic Fungal Infections in Children
Traditionally, the mainstay of systemic antifungal therapy has been amphotericin B deoxycholate (conventional amphotericin B). Newer agents have been developed to fulfill special niches and to compete with conventional amphotericin B by virtue of having more favourable toxicity profiles. Some agents...
Saved in:
| Main Author: | UD Allen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2010/784549 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fungal Infections, Treatment and Antifungal Resistance: The Sub-Saharan African Context
by: Emily Boakye-Yiadom, et al.
Published: (2024-11-01) -
Adverse events of modern antifungal drugs during treatment of invasive fungal infections
by: N. V. Dmitrieva, et al.
Published: (2014-07-01) -
The Role of Antifungals in Pediatric Critical Care Invasive Fungal Infections
by: Ashlesha Kaushik, et al.
Published: (2018-01-01) -
Advancing global antifungal development to combat invasive fungal infection
by: Xiu-Li Wang, et al.
Published: (2025-08-01) -
Fighting Fungal Threats: Verification of an antifungal susceptibility assay to improve antifungal stewardship in the management of Candida infections
by: Miss Ashleigh Hale, et al.
Published: (2025-03-01)